article thumbnail

Logistics in Focus: Orchestrating the Challenges of Cell Therapy

Conversations in Drug Development Trends

These advanced therapeutics harness the power of molecular biology to improve human health. Despite their exciting potential, the smooth operation of cell therapy development trials requires extraordinary orchestration, perfectly aligning the product and patient journeys.

article thumbnail

Organoids: the versatile platform for discovery and regeneration

Drug Target Review

Now take a step further: envision testing drugs in these organoids to identify the ones that can treat disease safely and effectively without needing to run expensive clinical trials first. He received his BS in physics and biology from the University of Chicago and his PhD in molecular biology from the University of Pennsylvania.

Treatment 105
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

De-risking drug discovery with predictive AI

Broad Institute

Still, more than 90 percent of drug candidates fail in clinical trials, with even more that never make it to the clinical stage. As of now, papers describing three of these machine learning tools have been published, in the Journal of Chemical Information and Modeling , Molecular Biology of the Cell , and Chemical Research in Toxicology.

article thumbnail

Sarah Wicks Returns to HPM to Elevate Drug Development and Regulatory Practice

FDA Law Blog: Drug Discovery

Her expertise spans a range of critical areas including: human subject protections, clinical trial conduct, development strategies, FDA interactions, and enforcement action responses. Sarah graduated with a cum laude degree in Cell and Molecular Biology from Towson University, a M.P.H.

article thumbnail

A surprising new role for a major immune regulator

Broad Institute

Drugs that activate STING have been developed and tested in clinical trials as cancer immunotherapy drugs that would help stimulate the immune system to destroy tumors. Food and Drug Administration has not approved any STING agonist thus far, although multiple clinical trials are currently underway. Paper Cited Liu B, Carlson R, et al.

article thumbnail

Leveraging ADCs in precision oncology strategy

Drug Target Review

Antibody-drug conjugates have seen explosive growth in the last few years which has materialised with numerous clinical trials demonstrating meaningful improvements in survival. How does the company see antibody-drug conjugates (ADCs) fitting into this approach?

article thumbnail

Scaling Phage Therapy

Codon

1 Yet even after more than two decades of research, media hype, and dozens of clinical trials and biotech start-ups that have come and gone, phage therapy has not scaled. No phage-based therapeutic has reached the latter stages of the clinical trial pipeline (where promising results lead to an expanded trial involving thousands of patients).

Therapies 124